Regulatory Strategic Planning Flashcards
7 cards from real RAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Regulatory Strategic Planning flashcards as text
Under 21 CFR Part 312, a Type B meeting with FDA is most commonly used to discuss:
Answer: End-of-Phase 2 issues and pre-NDA/BLA discussions
Type B meetings include End-of-Phase 1, End-of-Phase 2, pre-NDA/BLA, and pre-BLA meetings — they are milestone meetings that occur at defined stages of drug development.
In a global regulatory strategy, which factor most significantly influences the sequence of country submissions?
Answer: Commercial opportunity, unmet medical need, and regulatory complexity in each market
Submission sequence is strategically determined by factors including market potential, patient access urgency, regulatory precedent-setting value, and agency workload.
Which of the following best describes 'regulatory risk' in the context of a product development strategy?
Answer: The likelihood and impact of events that could delay or prevent regulatory approval
Regulatory risk encompasses the probability and potential impact of events—such as insufficient clinical data, manufacturing issues, or label disputes—that could jeopardize or delay approval.
A company's product has received a Complete Response Letter (CRL) from FDA. The strategic next step should be:
Answer: Carefully analyze the deficiencies cited and request a Type A meeting to discuss the path forward
After a CRL, analyzing the specific deficiencies and meeting with FDA (Type A meeting) to clarify the agency's concerns is the standard strategic response.
The FDA's 'Accelerated Approval' pathway allows approval based on:
Answer: A surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit
Accelerated Approval allows use of surrogate or intermediate clinical endpoints reasonably likely to predict clinical benefit, with post-approval confirmatory trials required.
In regulatory strategic planning for a new molecular entity (NME), the end-of-Phase 2 (EOP2) meeting is critical primarily because:
Answer: It aligns the Phase 3 program design with FDA's requirements before committing major resources
The EOP2 meeting allows sponsors to confirm that Phase 3 design, endpoints, and statistical approach meet FDA's requirements before investing in expensive pivotal trials.
Which regulatory strategy principle is illustrated when a company files for orphan drug designation before beginning Phase 3 trials?
Answer: Proactive lifecycle planning to secure incentives early in development
Filing for orphan designation proactively secures benefits including market exclusivity, tax credits, and fee waivers before Phase 3 investment, reflecting forward-looking lifecycle strategy.